Pages

Extrusion: Beyond Simple Tubing


Medical device manufacturers have traditionally relied on their extrusion supply partners for affordable medical tubing for a variety of application areas. However, more and more, these OEMs are seeking greater capabilities and more design solutions from these same supply parterners. This article looks at how medical extrusion is impacting device development today.

Tubing, tubing, and more tubing. That’s the traditional view of what an extruder offers to medical device manufacturers. Parts, like tubing, that have a continuous profile and are to be produced in long lengths are ideal candidates for extrusion. Unfortunately, when compared to injection molding, extrusion can suffer from a limitation in the tolerances able to be achieved. Due to the manufacturing process of an extruded part, a number of factors can impact the end product and thereby influence the tolerances achieved. However, extrusion also offers an array of benefits to medical device manufacturers for emerging technologies in areas including minimally invasive surgical devices, diagnostics, neuroradiology, electrostimulation, and more.
Once the tubing is formed, it travels through the area in which the material is heat cured (photo courtesy of Sil-Pro).Once the tubing is formed, it travels through the area in which the material is heat cured (photo courtesy of Sil-Pro).“As the designers of extrusion tooling continue to refine their craft, more and more complex shapes become capable for extrusion production. Specifically, the area of catheters has advanced medical procedures to new levels as surgeons enter the human body through smaller and smaller incisions. Extrusion-made probe tubes can bristle with all sorts of complex medical instruments that fit inside custom shaped cavities,” explains Paul Frechette, engineering manager at Pexco, a leader in the design and fabrication of extruded plastics products.
It is this sort of advanced capabilities that are being incorporated into more and more medical device technology. Catheters that enable doctors to access remote regions of a patient’s body without making large incisions are just one benefit. Extrusion makes it possible to deliver a host of devices to those same locations, enabling a variety of treatments to be carried out.
Claudia Aurand, global market manager with Teleflex Medical OEM—a single source provider of design, development, and production services—speaks more to this point. “The trend toward minimally invasive surgery techniques is the driving force behind smaller, more complex devices that require innovative design and manufacturing. A good example would be microcatheters, which are used for diagnostic and delicate therapeutic neuroradiology or occlusive therapies for the treatment of stroke and aneurisms. They require extrusion companies to possess a thorough understanding of catheter construction, and the deep expertise in advanced levels of precision manufacturing.”
Complex profiles, multiple lumens, and other features are becoming much more common requests for extrusion suppliers (photo courtesy of Vesta).Complex profiles, multiple lumens, and other features are becoming much more common requests for extrusion suppliers (photo courtesy of Vesta).With the continuous emergence of these minimally evasive technologies that are traveling through the canals fabricated from extrusion processes, designers are seeking more functionality and features in their catheters and other tubing products. Bill Woinowski, Vesta’s Silicone Division R&D manager—a leading medical device contract manufacturer—explains that customers are “seeking innovative extrusion solutions such as multi-durometer extrusions, increased radiopacity, higher pressure capabilities, and greater kink resistance.” He adds, “we are seeing an increase in the number of lumens and complexity of lumen configurations as our customers add functionality delivered through a single channel.”
Fortunately, along with the increased complexity designers are tasking their extrusion supply partners with, at the same time, they seem to be realizing the benefits of getting that partner on board earlier in the development process. “More of our customers are engaging us at the development stage and looking for innovative solutions to design challenges. There seems to be a movement in the medical device industry in this direction to utilize the capabilities and experience of suppliers earlier in the development process,” explains Mark Erson, QA director at Sil-Pro, a company that specializes in LEAN silicone molding and silicone extruding for a vast array of medical products.
Braided catheters offer advanced functionality and increased benefits to medical device manufacturers (photo courtesy of Teleflex Medical OEM).Braided catheters offer advanced functionality and increased benefits to medical device manufacturers (photo courtesy of Teleflex Medical OEM).While not likely to surpass molding in terms of the volume of product produced for medical devices, extrusion has certainly come a long way from simply being the process used for making a basic tube. “I think that medical device companies are looking to extrusion for complex profile shapes, multiple layer tubing, and fabrication to supplement their equipment,” agrees Frechette.
As extrusion continues to move toward offering more complex solutions for sophisticated, minimally invasive medical devices, design engineers will become more familiar (and comfortable) with the array of benefits, as well as the limitations, of the process. Getting the extrusion supplier on board early in the design process is certainly an ideal scenario for achieving the best results. However, at minimum, medical device designers need to at least explore the options with a reliable partner to determine if the process is even the right option for a product, Frechette explains, “There is no shortage of examples where medical device programs have failed or struggled because the designers learned too late in the process that their parts could not be produced in extrusion, whether by shape or tolerance level. Going back through the lengthy approval process for a device with design revisions is a daunting task for any medical project manager.
Sean 

A Matter of Materials


New material offerings are critical to medical device manufacturers as they provide new opportunities in the development of cutting edge technologies. This round-up features three new materials that are impacting medical device manufacturing in the areas of adhesives/coatings, molding, and extrusion.
 

Extrusion Material Focus
By Mathew Bills and Robert LaDuca
Natural colored PebaSlix resin alongside yellow colored PEBA resins, as well as a variety of extruded catheter tubing configurations and molded componentsNatural colored PebaSlix resin alongside yellow colored PEBA resins, as well as a variety of extruded catheter tubing configurations and molded componentsWith today’s medical catheters becoming increasingly smaller and more complex, it has become nearly impossible to meet new product performance requirements capable of enabling the next generation clinical applications without the development of new materials and the integration of those materials with existing manufacturing processing technologies. For example, the competing requirements for flexibility, ultrathin walls, torque response, and kink resistance are often combined with the need for lubricity—allowing the passage of other devices or motion between catheter surfaces.
The use of PTFE, FEP, or HDPE as a liner has been effective at lowering friction. These materials are often specified for catheter designs despite their limitations. For example the use of PTFE limits sterilization options, increases stiffness, has higher cost, and requires reflow processing complexities. Attempts to meet low friction requirements while avoiding the limitations of using existing material options in catheters has led to the development of hydrophilic coatings for interior lumens and the tubing’s exterior. This alternative, however, poses additional issues such as the requirement for an aqueous environment, which is not always present in many applications.
Other attempted solutions to the friction problem have been to add lubricious agents into the base resin of the tubing being produced. Several possibilities have been explored, from PTFE particles to erucamide additives. The PTFE particles may be distributed throughout the thermoplastic. However, due to the melting point difference between the fluoropolymer and the thermoplastic, the PTFE particles do not fully disperse into the thermoplastic resin, creating a less than optimal result. Adding erucamide to a base polymer will reduce the co-efficient of friction but, over a short period of time, it will leach to the surface of the tube, leaving a chalk-like contaminant substance that becomes source of particulation.
In seeking a solution to these problems, Duke Empirical has developed a class of new materials that are being introduced into the market called PebaSlix and PolySlix. These new materials are lubricious and have low friction by a proprietary patent pending process that combines certain additives with the backbone of PEBA and/or polyurethane. The additives are fully dispersed into the thermoplastic, utilizing the full benefit of the additive without changing the mechanical properties, processability, or sterilization methods. PebaSlix and PolySlix with their non-leaching, fully dispersed properties can be bonded and processed in the same manner as traditional PEBA and urethane and are available in a variety of durometers. Material biocompatibility testing is underway and master file data will soon be made available for customer’s regulatory applications. The chart shows the reduced coefficient of friction of PebaSlix compared to standard Pebax, as well as other, traditionally considered low-friction materials such as PTFE, FEP, and HDPE.
Mathew Bills is the director of extrusion technologies at Duke Extrusion, a division of Duke Empirical. Robert LaDuca is the founder and CEO of Duke Empirical.

Adhesives/Coatings Material Focus
By Jennifer Hooker
Improved medical grade silicone formulations have been instrumental in the development of new medical electronic devices. These compounds feature easy application, convenient cure schedules, sterilization resistant properties, biocompatibility, and are environmentally friendly. They offer unmatched flexibility, temperature resistance, and cost effectiveness. Medical electronic devices are now available in smaller sizes, lighter weight, and have enhanced performance properties. Silicone systems have played a vital role in meeting the increasing challenging requirements of the medical device industry and expand future possibilities.
Optically clear MS 151Med has a low viscosity, a convenient cure schedule, and is easy to apply.Optically clear MS 151Med has a low viscosity, a convenient cure schedule, and is easy to apply.One such material offering is the two component, room temperature curingMaster Bond MasterSil 151Med—a medical grade, potting and encapsulation silicone. Since flexibility is of vital importance in the design of medical devices subjected to vibration, impact, shock, and thermal cycling, this material is formulated to withstand such exposures. With a low viscosity of 1,500 cps, it is ideal for use in applications with complicated contours in very complex configurations. It is an excellent electrical insulator with a volume resistivity of 1x1015 ohm cm and can handle service over the wide temperature range of -65 to 400°F.
MasterSil 151Med cures optically clear with a refractive index of 1.43, making it well suited for use as a protective coating in optical and fiber optic applications. Cures can be accomplished at room temperature, or faster at elevated temperatures. Shrinkage upon cure is less than 0.1%. When cured, MasterSil 151Med has a Shore A hardness of 45 and an elongation at break of 160%. Even though it has such high elasticity, its tensile strength is still a favorable 880 psi at73°F. Mix ratio is 10 to 1 by weight. MasterSil 151Med fully meets USP Class VI requirements for medical applications.
Jennifer Hooker is a technical editor with Master Bond Inc. She has been reporting on new technology for over 7 years, both in the consumer and industrial markets.

Molding Material Focus
By Scott Young, Ph.D.
Novel products for individual therapies, such as imaging for diagnostics, new antibody treatments, biomarkers, tissue engineering, nanocarriers, and gene-based and stem-cell therapies, may reach the market by 2020.1 For many of these advanced pharmaceutical technologies, glass may not be the logical or preferred choice for containment and/or delivery. Technological advancements in therapeutics and diagnostics should be matched by innovations in containment and delivery systems.
The Daikyo Crystal Zenith polymer can be molded into containment systems suitable for a drug product’s life cycle.The Daikyo Crystal Zenith polymer can be molded into containment systems suitable for a drug product’s life cycle.Glass as a primary contact material for pharmaceutical and biopharmaceuticals has hurdles to overcome with respect to suitability. The need for silicone lubricants, breakage, particles, and leachables are among the major concerns. To combat the risks associated with glass, modern polymeric materials should be considered. The manufacture and processing of polymers allows for flexibility in molding and forming throughout a drug product’s lifecycle. Qualification of such materials is dependent on intended use, and risk assessments should be considered early to support development and protection of the drug product throughout its lifecycle.
The Daikyo Crystal Zenith cyclic olefin polymer (COP) is a class of polyolefins in which the performance characteristics are enhanced. The synthesis allows for better control of the molecular structure with fewer side reactions and less need for performance additives. Precision molding can be optimized for the intended use and once the materials are qualified, forming can be adapted as needed. This class of polymer has few ingredients and offers the desired properties of transparency and break resistance. It also provides a strong moisture barrier and is easy to sterilize.
Cyclic olefin polymers are high-performance materials possessing the valuable properties necessary to manufacture, store, protect, and deliver drug products without many of the weaknesses inherent to glass. It is especially suitable for biologic applications since many of the COP’s quality attributes specifically meet the challenging needs of this market.
Scott G. Young, Ph.D. is a senior director at West Pharmaceutical Services. He is responsible for the development and commercialization of the Daikyo Crystal Zenith Platform, including syringes, vials, API containers, and novel delivery systems.
1 Breakage and Particle Problems in Glass Vials and Syringes Spurring Industry Interest in Plastics. IPQ in the News 7, August 2011.

Motors Take on Cancer


The Project: A multi-leaf collimator device needed to offer greater levels of accuracy than any similar product on the market.
 

The Solution: Multiple devices were incorporated, including 180 motors, to shape gamma ray radiation therapy beams, controlled by one interlinked motion control system.
 

The EPOS2, brushless DC motor controllers are easy to install and implement using one of several major interfaces, plus are compact enough to keep the system’s footprint small.The EPOS2, brushless DC motor controllers are easy to install and implement using one of several major interfaces, plus are compact enough to keep the system’s footprint small.When it came to designing a multi-leaf collimator (MLC) device,ViewRay took on the challenge to produce an end product that would be more accurate than others on the market. ViewRay collaborated with Maxon Precision Motors for critical components, including a custom motherboard, motors, encoders, gearheads, and individual motor control modules, according to an engineering team member.
ViewRay Incorporated is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The ViewRay system provides continuous soft-tissue imaging during treatment, using MRI-guided radiotherapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient’s anatomy.
Overall, the ViewRay system includes five sub-systems, which are seamlessly integrated to provide optimal patient care. The major subsystems are: real time MR imaging, treatment planning, dose prediction and optimization, real time soft-tissue targeting, and remote review and approval. The treatment delivery is performed in a split-magnet MRI system with rotating gantry assembly to position three shielded Cobalt-60 sources with the three multileaf collimators.
ViewRay’s MRI-guided Radiotherapy System is designed using 180 motors and controllers for accurate gamma ray delivery. ViewRay’s MRI-guided Radiotherapy System is designed using 180 motors and controllers for accurate gamma ray delivery.The imaging in other radiotherapy technologies took place before or after treatment, not while the beam was on. This was a limitation in providing therapy because targeting could not be adjusted dynamically. Soft-tissue motion often allowed a tumor’s position to shift during treatment, causing soft tissue damage.
The ViewRay system solved this problem by using a combination of MR imaging and radiation therapy delivery technologies. With continuous soft-tissue imaging, during treatment and with the beam on, ViewRay tools can refine the target and re-optimize the dose while the patient is on the treatment table. This was the first MRI-guided Radiotherapy System produced.
According to the engineering team, “The MLC motor control system is a critical portion of the system. We knew it would also be one of the more challenging to design because of proximity to the MRI magnet, and volume constraints due to the gantry configuration.” The system uses three gamma ray sources, mounted in separate shielded heads. For ViewRay, the double-focused MLC is designed to sharpen field edges to produce penumbra comparable to conventional accelerators, so that clinicians can treat patients with greater confidence.
The team chose Maxon’s EPOS2 Module 36-2 compact digital positioning controllers for their small form factor, which allowed them to package 60 channels of motion control for each collimator. Thirty modules can fit on a single custom motherboard, and there are two motherboards per collimator. Each ViewRay system required three of these collimators, one for each of the three heads used in the system.
EPOS controllers are compact, fully digital, smart motion controllers designed for use as plug-in modules in customer-specific motherboards, and can be used for single-axis or multi-axis motion control systems. Each EPOS module implements a flexible and highly efficient power stage, and drives a brushed DC motor with digital encoder. They are especially designed to operate as a slave node in a CANopen network. They have a maximum current output capability of two amps, running from an eleven to thirty-six volt DC power supply.
This CAD drawing of one of the collimators, shows the motors extending from one of the sides. This CAD drawing of one of the collimators, shows the motors extending from one of the sides.In order to interface with the controllers, the ViewRay team used the resident EPOS2 firmware, which provided simple to implement operating modes and monitoring functions required by the control system. What made things easier was that the controllers are CANopen compatible, which allowed the design team to define up to 127 device addresses on a single bus segment.
Each of the collimators contains sixty leaves that are arranged in two opposing banks of thirty. Since there are three collimators, the device uses 180 EPOS controllers as well as 180 motor/encoder/gearhead assemblies. The MLCs are mounted on the gantry system to provide collimation of the three gamma radiation sources with respect to the target. While the gantry is moving into position, each collimator leaf is positioned according to the treatment plan. To position each leaf, CANopen bus commands are directed to the associated node consisting of a motor, encoder, gearhead, and controller. The result is a precisely collimated shape that matches the treatment plan.
The 180 motors used in the system are RE16 brushed DC, 4.5 Watt motors. Each motor operates at speeds up to 11,000 rpm. Along with the motors are MEnc13 Hall-effect encoders for precise motor control and GP16A gearheads with 19:1 reduction, providing adequate torque for positioning speeds of 1.0 cm per second.
The EPOS Studio software package provided an easy-to-learn, easy-to-use development environment for proof of concept and end-product development activities, according to engineering. Due to MRI magnetic field effects, the MLC controllers had to be remote from the motors, and housed in a convection-cooled chassis.
Paul McGrath is a regional sales engineer at maxon precision motors.